Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events

被引:357
作者
Mora, Samia [1 ,2 ,3 ,4 ,5 ]
Rifai, Nader [7 ]
Buring, Julie E. [3 ,4 ,6 ]
Ridker, Paul M. [1 ,2 ,3 ,4 ,5 ,6 ]
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Leducq Ctr Mol & Genet Epidemiol, Boston, MA 02215 USA
[3] Harvard Univ, Sch Med, Brigham & Womens Hosp, Donald W Reynolds Ctr Cardiovasc Res, Boston, MA 02215 USA
[4] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA
[5] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02215 USA
[6] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA
[7] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA
关键词
apolipoproteins; lipids; women;
D O I
10.1161/CIRCULATIONAHA.108.777334
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background - Although guidelines recommend measuring fasting lipids for initial screening of adults without cardiovascular disease (CVD), recent studies suggest that nonfasting triglycerides may be superior to fasting. Whether fasting status alters associations of nontriglyceride lipids with CVD is unclear. Methods and Results - In a prospective study of 26 330 healthy women (19 983 fasting; 6347 nonfasting), associations of baseline lipids with incident CVD (754 fasting; 207 nonfasting) were examined over an 11-year follow-up. Except for triglycerides, lipid concentrations differed minimally (<5%) for fasting versus nonfasting. However, stronger associations with CVD were noted for fasting total cholesterol (adjusted fasting hazard ratio [ HR], 1.22 per 1-SD increment; 95% CI, 1.14 to 1.30; nonfasting HR, 1.07; 95% CI, 0.93 to 1.21), low-density lipoprotein (LDL) cholesterol (fasting HR, 1.21; 95% CI, 1.13 to 1.29; nonfasting HR, 1.00; 95% CI, 0.87 to 1.15), apolipoprotein B-100 (fasting HR, 1.36; 95% CI, 1.27 to 1.45; nonfasting HR, 1.20; 95% CI, 1.05 to 1.36), non-high-density lipoprotein (HDL) cholesterol (fasting HR, 1.29; 95% CI, 1.21 to 1.38; nonfasting HR, 1.15; 95% CI, 1.01 to 1.31), and apolipoprotein B-100/A-1 ratio (fasting HR, 1.39; 95% CI, 1.30 to 1.48; nonfasting HR, 1.18; 95% CI, 1.09 to 1.27). Compared with fasting levels, nonfasting HDL cholesterol, apolipoprotein A-1, and total/HDL cholesterol ratio had similar associations, and triglycerides had a stronger association, with CVD. Significant interactions were seen for LDL cholesterol and apolipoprotein B-100/A-1 ratio with fasting status (P for interaction = 0.03 and < 0.001, respectively). Conclusions - This study demonstrates that HDL cholesterol, triglycerides, total/HDL cholesterol ratio, and apolipoprotein A-1 predict CVD when measured nonfasting. By contrast, total, LDL, and non-HDL cholesterol, in addition to apolipoprotein B-100 and B-100/A-1 ratio, provide less useful CVD risk information when nonfasting, despite small changes in their concentrations. Guidelines for lipid screening may need to consider these differences.
引用
收藏
页码:993 / 1001
页数:9
相关论文
共 28 条
[1]
BACHORIK PS, 1995, CLIN CHEM, V41, P1414
[2]
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women [J].
Bansal, Sandeep ;
Buring, Julie E. ;
Rifai, Nader ;
Mora, Samia ;
Sacks, Frank M. ;
Ridker, Paul M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (03) :309-316
[3]
Diurnal and acute patterns of postprandial apolipoprotein B-48 in VLDL, IDL, and LDL from normolipidemic humans [J].
Campos, H ;
Khoo, C ;
Sacks, FA .
ATHEROSCLEROSIS, 2005, 181 (02) :345-351
[4]
COHN JS, 1988, J LIPID RES, V29, P469
[5]
COHN JS, 1988, CLIN CHEM, V34, P2456
[6]
Low-dose aspirin in the primary prevention of cancer the women's health study: A randomized controlled trial [J].
Cook, NR ;
Lee, IM ;
Gaziano, JM ;
Gordon, D ;
Ridker, PM ;
Manson, JE ;
Hennekens, CH ;
Buring, JE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (01) :47-55
[7]
Blood cholesterol screening - Influence of fasting state on cholesterol results and management decisions [J].
Craig, SR ;
Amin, RV ;
Russell, DW ;
Paradise, NF .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2000, 15 (06) :395-399
[8]
European guidelines on cardiovascular disease prevention in clinical practice -: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts) [J].
De Backer, G ;
Ambrosioni, E ;
Borch-Johnsen, K ;
Brotons, C ;
Cifkova, R ;
Dallongeville, J ;
Ebrahim, S ;
Faergeman, O ;
Graham, I ;
Mancia, G ;
Cats, VM ;
Orth-Gomér, K ;
Perk, J ;
Pyörälä, I ;
Rodicio, JL ;
Sans, S ;
Sansoy, V ;
Sechtem, U ;
Silber, S ;
Thomsen, T ;
Wood, D .
ATHEROSCLEROSIS, 2003, 171 (01) :145-155
[9]
EFFECTS OF MODERATE AMOUNTS OF EMULSIFIED DIETARY-FAT ON POSTPRANDIAL LIPEMIA AND LIPOPROTEINS IN NORMOLIPIDEMIC ADULTS [J].
DUBOIS, C ;
ARMAND, M ;
AZAISBRAESCO, V ;
PORTUGAL, H ;
PAULI, AM ;
BERNARD, PM ;
LATGE, C ;
LAFONT, H ;
BOREL, P ;
LAIRON, D .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1994, 60 (03) :374-382
[10]
DUBOIS C, 1994, J LIPID RES, V35, P1993